This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-MAPB: Difference between revisions
>ChristopherFye Added a cite for legal status of 5-MAPB in Japan. |
>Melunaka m →Legal status: Fix typo |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
'''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]]. | '''5-(2-methylaminopropyl)benzofuran''' (abbreviated '''5-MAPB''') is a synthetic [[Psychoactive class::entactogen]] of the substituted [[chemical class::benzofuran]] class of chemicals, which are known to produce [[euphoria|euphoric]], [[entactogen]]ic, [[stimulant|stimulating]] and mildly [[hallucinogen]]ic effects. These include such [[MDA]]-inspired substances as [[5-APB]], [[6-APB]] and [[5-EAPB]], among others. 5-MAPB is the N-methylated form of [[5-APB]], analogously to how [[MDMA]] is the N-methylated form of [[MDA]]. | ||
This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | | This compound is known for its [[stimulating]], [[euphoria|euphoric]] and [[entactogen]]ic effects that is capable of acting a quasi-substitute for [[MDMA]] proper, which has resulted in its rise in popularity as a [[research chemical]] that is easily accessible through the use of online vendors. It has been sold as a [[designer drug]] since 2010.<ref>{{Citation | title=EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA | url=https://www.emcdda.europa.eu/publications/implementation-reports/2010}}</ref> | ||
5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 36% more potent by mass so doses should be adjusted accordingly.{{citation needed}} | 5-MAPB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 36% more potent by mass so doses should be adjusted accordingly.{{citation needed}} | ||
| Line 13: | Line 13: | ||
==Pharmacology== | ==Pharmacology== | ||
5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>The effects of benzofury (5- | 5-MAPB is a triple [[reuptake inhibitor]] for the [[monoamines]] [[norepinephrine]], [[dopamine]] and [[serotonin]] as well as being an [[agonist]] for the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] and [[Serotonin#The_5-HT_system|5-HT<sub>2B</sub>]] [[receptor]]s.<ref>{{cite journal | vauthors=((Dawson, P.)), ((Opacka-Juffry, J.)), ((Moffatt, J. D.)), ((Daniju, Y.)), ((Dutta, N.)), ((Ramsey, J.)), ((Davidson, C.)) | journal=Progress in Neuro-Psychopharmacology & Biological Psychiatry | title=The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat | volume=48 | pages=57–63 | date=3 January 2014 | issn=1878-4216 | doi=10.1016/j.pnpbp.2013.08.013}}</ref><ref>{{cite journal | vauthors=((Iversen, L.)), ((Gibbons, S.)), ((Treble, R.)), ((Setola, V.)), ((Huang, X.-P.)), ((Roth, B. L.)) | journal=European Journal of Pharmacology | title=Neurochemical profiles of some novel psychoactive substances | volume=700 | issue=1 | pages=147–151 | date=30 January 2013 | url=https://www.sciencedirect.com/science/article/pii/S0014299912010114 | issn=0014-2999 | doi=10.1016/j.ejphar.2012.12.006}}</ref> It has also been speculated that 5-MAPB acts as a [[releasing agent]] for the previously mentioned [[neurotransmitters]]. | ||
As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects. | As a result, releasing agents such as [[5-MAPB]] may exert their activity by effectively boosting the levels of the serotonin, norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally clear and reuptake those monoamines from the synaptic cleft. This allows serotonin, dopamine and norepinephrine to accumulate within various reward and cognition-related areas in the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects. | ||
| Line 102: | Line 102: | ||
{{legalStub}} | {{legalStub}} | ||
*'''France''': 5-MAPB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.<ref>{{cite web|url=https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000043529751|title=Article Annexe IV - Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants|publisher=Légifrance|access-date=September 23, 2022|language=fr}}</ref> | |||
*'''Germany''': 5-MAPB is controlled under the NpSG (New Psychoactive Substances Act)<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> | *'''Germany''': 5-MAPB is controlled under the NpSG (New Psychoactive Substances Act)<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 18, 2019|language=de}}</ref> | ||
*'''Japan''': 5-MAPB is a controlled substance in Japan effective August 15th, 2015.<ref>[https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/ihou-drug/20140815.html "平成26年8月15日付けで以下の21物質が指定薬物に指定されました。（施行日：平成26年8月25日）"] (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved on May 2, 2022.</ref> | *'''Japan''': 5-MAPB is a controlled substance in Japan effective August 15th, 2015.<ref>[https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/ihou-drug/20140815.html "平成26年8月15日付けで以下の21物質が指定薬物に指定されました。（施行日：平成26年8月25日）"] (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved on May 2, 2022.</ref> | ||